Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications

Assessment of Health‐Related Quality of Life in Patients With Cystinuria on Tiopronin Therapy

View
Publications

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

View
Publications FSGS

Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

View
Publications FSGS

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

View
Publications

Accurate 24‐h Urine Cystine Quantification for Patients on Cystine‐Binding Thiol Drugs

View
Publications FSGS

Efficacy and Safety of Sparsentan Compared with Irbesartan in Patients with Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

View
Publications

Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis

View
Publications IgAN

The Humanistic Burden of Immunoglobulin A Nephropathy on Patients and Care-Partners in the United States

View
Publications

Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease

View
Publications IgAN

Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial

View
Publications FSGS

Sparsentan Improves Glomerular Hemodynamics, Cell Functions and Tissue Repair in a Mouse Model of FSGS

View
Publications IgAN

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy

View
Publications IgAN

Sparsentan Ameliorates Glomerular Hypercellularity and Inflammatory-gene Networks Induced by IgA1-IgA Immune Complexes in a Mouse Model of IgA Nephropathy

View